Atika Capital Management LLC Sells 1,500 Shares of Glaukos Co. (NYSE:GKOS)

Atika Capital Management LLC trimmed its position in Glaukos Co. (NYSE:GKOS) by 0.6% in the fourth quarter, Holdings Channel reports. The firm owned 239,500 shares of the medical instruments supplier’s stock after selling 1,500 shares during the quarter. Glaukos accounts for 3.8% of Atika Capital Management LLC’s holdings, making the stock its 4th biggest holding. Atika Capital Management LLC’s holdings in Glaukos were worth $35,911,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc bought a new position in shares of Glaukos in the 4th quarter worth about $43,000. Asset Planning Inc bought a new position in Glaukos during the 4th quarter worth $90,000. Picton Mahoney Asset Management bought a new position in Glaukos during the 4th quarter worth $125,000. SBI Securities Co. Ltd. acquired a new stake in Glaukos in the fourth quarter worth $153,000. Finally, Smartleaf Asset Management LLC lifted its stake in Glaukos by 275.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 807 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GKOS shares. Piper Sandler restated an “overweight” rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and raised their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Finally, Needham & Company LLC boosted their price target on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Trading Down 3.9 %

Shares of Glaukos stock opened at $83.62 on Friday. The business has a fifty day simple moving average of $123.88 and a 200-day simple moving average of $134.61. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of -29.14 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, equities analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Activity at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.